Overview of palmoplantar pustulosis:

Palmoplantar pustulosis (PPP) is a rare, recurrent inflammatory disease. People affected by the condition develop small or large sterile blisters (pustules) filled with a yellowish, cloudy fluid on the palms of the hands and soles of the feet. These pustules can be painful and often cause a burning sensation. The exact cause of PPP is still unknown, but researchers have suggested possible triggers such as smoking, bacterial infections (such as chronic tonsillitis, dental infections, and chronic sinusitis), contact allergies (especially to metals), and certain medications. Common symptoms include red, tender skin, blisters or pustules on the palms and soles of the feet, itching, pain, cracked skin, scaly patches, and dry, thickened skin. There is no cure for PPP, but treatments can help manage the symptoms.

Request a detailed Palmoplantar Pustulosis Pipeline Insights Report @ https://www.delveinsight.com/report-store/palmoplantar-pustulosis-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr

of Palmoplantar pustulosis pipeline insights 2025 DelveInsight's report provides a comprehensive analysis of the ongoing clinical development activities and growth prospects in the Palmoplantar Pustulosis Treatment market.

Key Takeaways from the Palmoplantar Pustulosis Pipeline Report:

DelveInsight's Palmoplantar Pustulosis Pipeline report highlights a dynamic space with over 8 active players working on developing over 8 pipeline therapies for the treatment of palmoplantar pustulosis. Key players such as Kyowa Kirin Co., Ltd., Aristea Therapeutics Inc., AnaptysBio, Inc., Boehringer Ingelheim, and Janssen Biotech are evaluating novel drugs to improve the treatment landscape for palmoplantar pustulosis. Promising pipeline therapies at various stages of development include KHK4827 (brodalumab), imsidolimab, and others.

Recent advances in the palmoplantar pustulosis pipeline:

Spesolimab, an anti-IL-36 receptor antibody, was approved by the FDA in March 2025 for the treatment of flare-ups of generalized pustular psoriasis (GPP) in patients aged 12 years and older. However, a clinical trial evaluating the efficacy of spesolimab in PPP failed to meet its primary endpoint of a significant reduction in PPP severity.

Palmoplantar pustulosis pipeline analysis:

This report provides insights into:

• A detailed study of key companies developing therapies in the Palmoplantar Pustulosis market.
  
  
• Evaluation of various therapeutic candidates categorized into early, mid, and late stage development for the treatment of palmoplantar pustulosis.
  
  
• Analysis of key companies involved in the development of targeted therapeutics, including both active and inactive (dormant or discontinued) projects.
  
  
• Insights into new drugs in development based on development stage, route of administration, target receptor, monotherapy or combination, mechanism of action and molecule type.
  
  
• It offers an in-depth analysis of collaborations (company-to-company and company-academia), licensing agreements, and funding details to advance the Palmoplantar Pustulosis market.
  
  

Download free sample page report on Palmoplantar Pustulosis Pipeline Insights: https://www.delveinsight.com/sample-request/palmoplantar-pustulosis-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr 

New drugs for palmoplantar pustulosis:

• KHK4827 (Brodalumab) : Kyowa Kirin Co., Ltd.
  
  
• Imcidoli : Anatis Bio Co., Ltd.
  
  

Palmoplantar pustulosis companies:

At least eight major companies are working on developing treatments for PPP, including Kyowa Kirin Co., Ltd., which is conducting Phase III clinical development of a candidate drug for PPP.

DelveInsight's report covers over eight products across various stages of clinical development.

• Late-stage products (Phase III)
  
  
• Mid-stage products (Phase II)
  
  
• Early Stage Products (Phase I) Along with details of preclinical and discovery stage candidates
  
  
• Discontinued and inactive candidates
  
  

The Palmoplantar Pustulosis Pipeline report provides therapeutic assessment of pipeline drugs based on: Route of administration (ROA). Products are categorized based on different ROAs, such as:

• Intravenous
  
  
• Subcutaneous
  
  
• Oral
  
  
• Intramuscular
  
  

Palmoplantar pustulosis products are also classified in various ways. Molecular Type , include:

• Monoclonal antibodies
  
  
• Low molecular weight
  
  
• peptides
  
  

Download the sample page to view a detailed assessment of emerging Palmoplantar Pustulosis treatments and key players: Palmoplantar Pustulosis Clinical Trials and Advancements @ https://www.delveinsight.com/report-store/palmoplantar-pustulosis-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr

Palmoplantar pustulosis pipeline treatment evaluation:

• Palmoplantar pustulosis evaluation by product type
  
  
• Stages of palmoplantar pustulosis
  
  
• Evaluation of palmoplantar pustulosis by route of administration
  
  
• Evaluation of palmoplantar pustulosis by molecular typing
  
  

For more detailed information on the Palmoplantar Pustulosis Treatment market, download the Palmoplantar Pustulosis Treatment Sample Report @ https://www.delveinsight.com/sample-request/palmoplantar-pustulosis-pipeline-insight?utm_source=reportutm_medium=promotionutm_campaign=hpr

Table of contents

1. Introduction to the report
2. Executive Summary
3. Current treatment patterns for palmoplantar pustulosis
4. Palmoplantar pustulosis - DelveInsight Analytical Perspective
5. Treatment evaluation
6. Palmoplantar pustulosis late-stage product (Phase III)
7. Palmoplantar pustulosis mid-stage product (Phase II)
8. Early Stage Products (Phase I)
9. Preclinical and discovery stage products
10. Inactive Products
11. Dormant products
12. Discontinued Products for Palmoplantar Pustulosis
13. Palmoplantar Pustulosis Product Profile
14. Major Palmoplantar Pustulosis Manufacturers
15. Main products for palmoplantar pustulosis
16. Inactive and Discontinued Products
17. Unmet Needs for Palmoplantar Pustulosis
18. Future prospects for palmoplantar pustulosis
19. Palmoplantar pustulosis analyst review
20. Appendix
21. Reporting Methods

Contact Information:

Himanshu

hmason@delveinsight.com

info@delveinsight.com

+14699457679

About DelveInsight

DelveInsight is a leading business consultancy and market research firm focused on life sciences, supporting pharmaceutical companies by providing comprehensive end-to-end solutions to improve their business performance.